Is it time to abandon complete blinded independent central radiological evaluation of progression in registration trials?-Reference-Cited by-同舟云学术

Is it time to abandon complete blinded independent central radiological evaluation of progression in registration trials?

Published:2011-08 Issue:12 Volume:47 Page:1759-1762
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Pignatti Francesco,Hemmings Rob,Jonsson Bertil

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference9 articles.

1. Guideline on the evaluation of anticancer medicinal products in man; 2006. Available from: http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500017748.

2. Guidance for industry, clinical trial endpoints for the approval of cancer drugs and biologics; 2007. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf.

3. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1);Eisenhauer;Eur J Cancer,2009

4. Progression-free survival remains debatable endpoint in cancer trials;Tuma;J Natl Cancer Inst,2009

5. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group;Stone;Eur J Cancer,2011

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progression-free survival assessment by local investigators versus blinded independent central review in randomized clinical trials in metastatic breast cancer: A systematic review and meta-analysis;European Journal of Cancer;2024-01

2. What is the weight of expectation bias in oncology trials?;British Journal of Clinical Pharmacology;2023-02-11

3. Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Phase 2 Oncology Trials;The Journal of Clinical Pharmacology;2020-12-15

4. A comparison between the assessments of progression-free survival by local investigators versus blinded independent central reviews in phase III oncology trials;European Journal of Clinical Pharmacology;2020-05-24

5. Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis;BMJ;2019-09-18